Valvular heart disease
Conditions
Interventions
Low-dose Remimazolam Tosilate group:Remimazolam Tosilate
High-dose Remimazolam Tosilate group:Remimazolam Tosilate
Sponsors
The Affiliated Hospital of Guizhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with heart valve replacement; 2. ASA grade I-III; 3. Aged from 18 to 65 years, male and female; 4. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to or contraindicated to benzodiazepines, etomidate;opioids, propofol, naloxone and their components; 2. Participated in other clinical trials within 4 weeks before operation; 3. Severe cardiac insufficiency, ASA grade IV and above; 4. Patients with uncontrolled or poorly controlled hypertension; 5. Abnormal liver and kidney function: ALT and/or AST exceeding 1.5 times the upper limit of the medical reference range, creatinine exceeding the upper limit of the medical reference range; 6. Patients with myasthenia gravis or mental disorders; 7. Long term drinking or using benzodiazepines and opioids; 8. Patients with expected difficult airway.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MAP change value during induction of general anesthesia;HR change value during induction of general anesthesia;Incidence of cardiovascular adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Use of vasoactive drugs;Glucose; | — |
Countries
China
Contacts
Public ContactHu Bailong
The Affiliated Hospital of Guizhou Medical University
Outcome results
None listed